Boston Scientific disclosed a cyberattack that disrupted global IT systems and order-shipping capabilities, leaving the company unable to provide a timeline for restoring normal operations. The incident adds to a growing list of med-tech breaches this year and raises operational continuity concerns for regulated supply chains. The company said it is still investigating the scope, nature, and impacts of the attack, including downstream effects on customers. For biotech and med-tech-facing partners, the disclosure underscores the need to harden manufacturing and logistics systems against ransomware and other intrusion vectors. The incident also highlights the downstream risk to clinical workflows when order processing and distribution are interrupted, especially for devices and diagnostic tooling that support ongoing patient care.